About Helomnix
Helomnix develops biologically grounded digital twins to support precision medicine in hematological diseases, including leukemia, multiple myeloma, and lymphoma.
The Helomnix platform integrates multi-omics data and curated biological knowledge to structure disease heterogeneity into interpretable functional states. These digital twins provide a framework for understanding disease mechanisms, exploring biomarkers, and supporting patient stratification in translational research and drug development.
Helomnix operates at the interface of computational biology, clinical expertise, and data-driven modeling, with a strong emphasis on interpretability, scientific rigor, and evidence traceability.
The company is being formed in close collaboration with academic, clinical, and industrial partners to advance precision hematology programs through reproducible, biology-first analytical workflows.
Learn More About What We Do
Interested in our approach to precision hematology? Get in touch or explore our partnership models.